Targeting glycolysis in endothelial cells to prevent intraplaque neovascularization and atherogenesis in mice

Perrotta, P.

Citation

Perrotta, P. (2021, March 24). *Targeting glycolysis in endothelial cells to prevent intraplaque neovascularization and atherogenesis in mice*. Retrieved from https://hdl.handle.net/1887/3152433

Cover Page

The handle https://hdl.handle.net/1887/3152433 holds various files of this Leiden University dissertation.

Author: Perrotta, P.
Title: Targeting glycolysis in endothelial cells to prevent intraplaque neovascularization and atherogenesis in mice
Issue Date: 2021-03-24

Chapter 5

Small molecule 3PO inhibits glycolysis but does not bind to 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3)

Emini Veseli B*, **Perrotta P***, Van Wielendaele P, Lambeir A, Abdali A, Bellosta B, Monaco G, Bultynck G, Martinet W, De Meyer GRY.

* The first two authors contributed equally to this work

Abstract

6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3 (PFKFB3) is a key enzyme of the glycolytic pathway and it plays an essential role in angiogenesis. 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) is frequently used as a glycolysis inhibitor and is thought to inhibit PFKFB3. However, this latter effect of 3PO has never been investigated in detail and was the aim of the present study. To demonstrate binding of 3PO to PFKFB3, we used isothermal titration calorimetry. However, 3PO did not bind to PFKFB3, even up to 750 µM, in contrast to 3 µM of AZ67, which is a potent and specific PFKFB3 inhibitor. Instead, 3PO accumulated lactic acid inside the cells, leading to a decrease in the intracellular pH and an inhibition of enzymatic reactions of the glycolytic pathway.

Keywords: glycolysis, PFKFB3, 3PO, intracellular pH, isothermal titration calorimetry

Introduction

Glycolysis is an essential bioenergetic pathway in endothelial cells (ECs) generating up to 85% of total cellular ATP. A key regulating enzyme in the glycolytic pathway is 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB), which is involved in both synthesis and degradation of fructose-2,6-bisphosphate. Among the four known PFKFB isoforms, only PFKFB3 reveals a kinase to phosphatase ratio of about 740:1, which favors the formation of intracellular fructose-2,6-bisphosphate (Fru-2,6-P_2) and enhanced glycolysis.[1, 2] Interestingly, expression of PFKFB3 is upregulated in response to hypoxia and inflammatory stimuli.[3, 4]. Because silencing or inactivation of PFKFB3 reduces glycolysis and impairs vessel sprouting [5], PFKFB3 has become an attractive therapeutic target in preventing pathological angiogenesis. 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) has been reported as a novel compound that reduces glycolytic flux through competitive inhibition of PFKFB3. [6] It causes a rapid reduction in Fru-2,6-P_2 levels and inhibits tumorigenic growth *in vivo.* It also diminishes ^{18}F-2-DG uptake within xenografts [6] and inhibits EC proliferation and migration, resulting in reduced vessel sprouting in EC spheroids, zebrafish embryos, and the postnatal mouse retina. Notably, all these effects of 3PO are attributable to only partial and transient inhibition of glycolysis. [7]

Although 3PO and the more potent analogue PFK15 are considered to act as PFKFB3 inhibitors [8-12], thorough experimental evidence is currently lacking. Moreover, recent data indicate that 3PO is inactive in a PFKFB3 kinase assay (IC_{50} >100 µM) and no crystal structure is available confirming binding of 3PO to PFKFB3 kinase. [13] It should be noted that 3PO does not inhibit the enzymatic activity of other enzymes involved in the glycolytic pathway such as hexokinase, glucose-6-phosphate dehydrogenase, transketolase, phosphofructokinase, pyruvate kinase and lactate dehydrogenase.[7] In the present study, we demonstrate that the anti-glycolytic activity of 3PO relies on its ability to interfere with intracellular milieu acidification, rather than on a direct binding to PFKFB3.

Materials and methods

Glycolysis measurements

Glycolysis was measured *in vitro* using a Glycolysis Cell-Based Assay Kit (Cayman Chemical) following the manufacturer's instructions. Briefly, human umbilical vein endothelial cells (HUVECs) were seeded in a 96-well culture plate at a density of 15,000 cells/well and incubated overnight at 37°C in M199 culture medium, supplemented with 0.25% heat-inactivated fetal calf serum (FCS), 1% non-essential amino-acids (NEAA), and antibiotics. Thereafter, cells were treated with 3PO (Sigma; 2-100 µM) for 24 h and assayed to determine the L-lactate concentration in the culture medium. A neutral red viability assay was performed as described [14] to test cell viability.

Glycolytic flux was also assessed in HUVECs by measuring the extracellular acidification rate (ECAR) using a Seahorse XFp Analyzer (Agilent Technologies) and following manufacturer recommended protocol. ECAR values were expressed in units of mpH/min, which follow the changes in pH in the media surrounding the cells, an acidification mostly due to glycolytic proton efflux [15]. Assays were performed prior to experiments to determine optimal cell seeding density, viability, and optimal concentrations of each compound. Briefly, 10,000 HUVECs/well were plated into XF8 polystyrene cell culture plates. After 16 h of incubation at 37°C, cells were treated with 3PO (0, 20 or 40 µM) for 5 h. Prior to performing a glycolysis stress test, growth medium in the wells of XF cell plates was exchanged with the appropriate Seahorse assay medium (Agilent Technologies, 103335-100). Baseline rates were measured three times prior to any injection. Firstly, glucose (Sigma Aldrich, G8270; 10 mM final concentration) was injected into the medium to provide a measure of glycolytic rate. Subsequently, oligomycin, a mitochondrial ATP synthase inhibitor (Sigma Aldrich, 75351; 2 µM final concentration) was injected, blocking oxidative phosphorylation and giving an estimate of glycolytic capacity. Finally, 2-DG (Sigma Aldrich, D8375; 50 mM final concentration) was injected, which is a glucose analog that inhibits glycolysis, providing an estimate of non-glycolytic acidification. All compounds were prepared in assay medium and adjusted to pH 7.4. Glycolytic

capacity was calculated as the difference between ECAR following the injection of 2 µM oligomycin and the basal ECAR reading. [16]

Intracellular lactate measurements

Intracellular lactate levels were measured *in vitro* using an L-Lactate Assay Kit (Cayman Chemical) according to the manufacturer's protocol. HUVECs were plated into a cell culture plate until 80% confluency in M199 growth medium supplemented with 20% FCS, 1% non-essential amino-acids, and antibiotics. Next, HUVECs were treated with 3PO (20 µM) or vehicle (DMSO) for 24 h. A cell count was performed with an automated cell counter (Countess® II FL, Life Technologies). After deproteinization with 0.25 M metaphosphoric acid, potassium carbonate (5 M) was added to the cell pellet to neutralize the acid. Following centrifugation (10,000 x g for 5 min) at 4˚C, the supernatant was used for assaying. Lactate fluorescent substrate was used as a fluorophore while fluorescence (λ_{ex}=540 nm; λ_{em}=595 nm) was measured and normalized to the cell number. 2-Cyano-3-(4-hydroxyphenyl)-2-propenoic acid (CHC), a classical inhibitor of monocarboxylate transporters, was used as a reference compound.

Intracellular pH assay

Intracellular pH changes were measured with a Fluorometric Intracellular pH assay kit (Sigma-Aldrich, MAK150) following the manufacturer's protocol. In brief, HUVECs were plated overnight in M199 growth medium supplemented with 20% FCS, 1% non-essential aminoacids, and antibiotics in a 96-well culture plate. Subsequently, the fluorescent pH indicator BCFL-AM was added for 30 min. 3PO (20µM) was diluted in Hank's Buffer (HBSS) containing 20 mM HEPES and added to the cells. Fluorescence (λ_{ex}=490 nm; λ_{em}=535 nm) was measured 5 h after addition of 3PO. 2-Cyano-3-(4-hydroxyphenyl)-2-propenoic acid (CHC), a well-known inhibitor of monocarboxylate transporters, was used as a reference compound.

In vitro angiogenesis assay

Inhibition of endothelial tube formation by 3PO was monitored using an *in vitro* angiogenesis assay kit (Millipore) following the manufacturer's instructions. Briefly, HUVECs were cultured in M199 medium supplemented with 20% FCS, 1% non-essential amino-acids, and antibiotics. After addition of 3PO (0-20 μM) for 16 h, changes in tube formation and formation of cellular networks were evaluated. Capillary tube branching points were counted in 5 random fields per concentration.

Endothelial cell migration assay

Murine immortalized heart ECs (H5V) were cultured on 12-well plates in DMEM medium supplemented with 10% FCS and antibiotics. After reaching confluence, H5V were starved overnight in DMEM containing 0.5% FCS. Each well was marked below the plate surface by drawing a vertical line. Five different scratches intercepting the marked line were done in each well using a 200 μL sterile tip. Pictures of scratches were taken before and after 18 hours incubation with DMEM (with 2.5% FCS) with or without 3PO (20 μM) and with or without vascular endothelial growth factor (VEGF, 10 ng/mL). Next, the mean closure of five different scratches was analyzed using ImageJ software. EC migration was expressed as the percentage of scratch closure after 18 h versus the initial area by using the following formula: % closure = [(scratched area at 0 h − scratched area at 18 h)/scratched area at 0 h] ×100.

Aortic sprouting

An aortic ring assay was performed as previously described. [17] In brief, murine thoracic aortas were dissected, cleaned under sterile conditions, transferred to 10 cm culture dishes, and cut into 0.5 mm thick rings with a sterile scalpel. After overnight starvation in serum-free Opti-MEM at 37°C, ring segments were transferred into wells of a 96-well plate coated with 50 μL of a freshly prepared collagen type I solution (1 mg/mL). The aortic rings remained in Opti-MEM (supplemented with 2.5% FCS and antibiotics) in the presence or absence of 3PO

and/or VEGF (50 ng/mL) (R&D Systems). Medium was replaced every 2 days. On day 6, rings were fixed with 4% paraformaldehyde, stained with von Willebrand factor antibody (anti-vWF, PC054, Binding Site) and DAPI prior to fluorescence microscopy imaging. The number of sprouts was counted for each ring and sprout numbers per ring were averaged for each group and graphed.

Isothermal Titration Calorimetry (ITC)

Binding of 3PO and AZ PFKFB3 67 (further abbreviated as AZ67, Tocris, used as control) to PFKFB3 was analyzed by calorimetry using a MicroCal Peaq-ITC isothermal titration calorimeter (non-automated version, Malvern Preanalytical). Prior to ITC analysis, recombinant human PFKFB3 from *E. coli* (Flemish Institute for Biotechnology (VIB), Protein Service Facility, University of Ghent, Belgium) was dialyzed against 2 L buffer (40 mM Tris, 500 mM NaCl, 5 mM $MgCl_2$, 2 mM DTT at pH 7.4) for 2 h at 4 °C under constant stirring, followed by switching to a novel 2 L buffer vial and overnight dialysis. For this purpose, Slide-A-Lyzer Dialysis G2 cassettes (Thermo Scientific) were used. The concentration of the sample after dialysis was determined through UV-absorbance at 280 nm using a Spectramax Plus 384 (Molecular Devices). A small portion of the second dialysis buffer volume was kept for matching the ligand solutions (AZ67 or 3PO). All buffers were prepared in ultrapure water (18.2 MΩ.cm), equilibrated to room temperature and degassed for 15 min in an ultrasonication bath before use. All titrations were performed with the same PFKFB3 sample, diluted to a working concentration of 3 µM, and with the same titration conditions (except for the ligand concentration) in order to allow mutual comparison between the different runs.

The reference cell of the Peaq-ITC was filled with degassed ultrapure water. The PFKFB3 solution was put in the sample cell after a 2 min pre-equilibration with assay buffer (same recipe as dialysis buffer). The ligand solution was administered in the injection syringe. Titration conditions were as follows: one initial injection of 0.4 µL was followed by 14 injections of 2.5 µL. The initial spacing was set to 180 s, while the remaining spacing was set to 150 s. The sample cell was continuously stirred at 750 rpm. Temperature was set to 37 °C before loading and kept constant during the

complete run. The DP (differential power between the reference and sample cells to maintain a zero temperature difference between the cells) was set to 5.

To determine the dilution heats for each PFKFB3-ligand concentration combination, control titrations were performed consisting of injection of ligand into the buffer-filled cell (thus in the absence of PFKFB3, without binding). Thermograms were analyzed using the Microcal Peaq-ITC Analysis software, using the 'one set of sites' binding model, by including the corresponding control titration. In order to visually compare the different titrations with completely different molar ratios, the data were transformed to generated heat (ΔH) per injection.

Statistics

All data are expressed as mean ± SEM. Statistical analyses were performed using SPSS software (version 25). Statistical tests are specified in the figure legends. N indicates the number of times an experiment has been repeated. Differences were considered significant at $P < 0.05$.

Results

3PO inhibits glycolysis in endothelial cells

Lactate measurements in the culture medium of human umbilical vein endothelial cells (HUVECs) as well as Seahorse ECAR measurements showed that 3PO inhibits glycolysis in a concentration-dependent manner (Figure 1A-B). The extracellular acidification rate diminished by more than 50% after treatment with 20 µM 3PO (Figure 1B). Viability of HUVECs was not affected when cells were treated with 3PO up to 20 µM (Figure 1C). However, cytotoxic effects were noticed after exposure to higher 3PO concentrations (40 and 100 µM).

Figure 1. **3PO inhibits glycolysis *in vitro*.** (A) Human umbilical vein endothelial cells (HUVECs) were cultured and treated with 3PO (2 – 100 μM) for 24 h. Extracellular lactatewas measured to evaluate glycolysis. (B) Glycolytic flux was assessed by measuring the extracellular acidification rate (ECAR) using a Seahorse XFp Analyzer. Cultured HUVECs were treated without or with 3PO (20 or 40 μM) for 5 h. (C) 3PO (2, 10, 20 μM) did not show cytotoxic effects up to 24 h treatment compared to vehicle (DMSO), whereas concentrations starting from 40 μM 3PO onward decreased cell viability. $**P<0.01$, $***P<0.001$ (one-way analysis of variance (ANOVA) followed by Dunnett test, n=3).

3PO inhibits capillary tube formation, EC migration, and formation of aortic sprouts

To confirm whether glycolysis inhibition by 3PO in ECs affects neoangiogenesis, an *in vitro* matrigel assay with HUVECs was performed. This assay is based on the ability of ECs to form cord and mesh structures when seeded on a growth factor-enriched matrix. 3PO fully inhibited cord formation at 20 μM. At lower concentrations (5-10 μM), mesh structures consisting of EC chords were visible but their numbers were reduced in a concentration-dependent manner. A healthy network of chord structures was formed in the absence of 3PO (Figure 2A). Branch point counting demonstrated an inverse correlation between the amount of branch points and the concentration of 3PO (Figure 2B). Apart from inhibition of capillary tube formation, 3PO inhibited EC migration after scratching EC monolayers (Figure 3) and prevented aortic sprouting (Figure 4) both under basal conditions and after stimulation with VEGF.

Figure 2. 3PO inhibits endothelial cell tube formation. (A) Representative images of an *in vitro* angiogenesis assay. Human umbilical vein endothelial cells (HUVECs) were seeded on ECMatrix in the presence or absence of 3PO (5, 10, 20 µM) for 16 h. Images of tube formation and branching were taken and quantified. Scale bar = 100 µm. (B) The progression of angiogenesis was quantified by counting the amount of capillary tube branch points at different concentrations. *P<0.05 vs. control (Mann-Whitney U test, n=4).


Figure 3. 3PO inhibits endothelial cell migration. (A) Representative images of a scratch assay. Murine immortalized heart endothelial cells (H5V) were starved, subsequently wounded and treated with DMEM (2.5% FCS) with or without 20 µM 3PO, and with or without

10 ng/mL VEGF for 18 h. (B) The wound area was measured at 0 and 18 h, and migration was quantified. Factorial ANOVA, n=5-7; effect of 3PO: P=0.020; effect of VEGF: P=0.046; interaction: P=0.255.


Figure 4. 3PO inhibits aortic sprouting. (A) Aortic rings from ApoE$^{-/-}$ mice were embedded in collagen type I and treated with Opti-MEM (supplemented with 2.5% FCS) in the presence or absence of 20 μM 3PO and/or VEGF (50 ng/mL) 2.5% (vol/vol) FBS or VEGF 50 ng/mL. At day 6, rings were fixed and stained to delineate ECs. Images of ring sprouting were obtained and quantified. Scale bar = 1 mm. (B) Sprouts were quantified, n=4 mice. ***P<0.001 Factorial ANOVA, effect of 3PO: P<0.001, effect of VEGF: P<0.001, interaction: P<0.001.

3PO does not bind PFKFB3

Isothermal titration calorimetry measurements did not show any binding of 3PO towards recombinant PFKFB3. Even usage of 750 μM 3PO as final concentration did not yield any binding indication. In contrast, AZ67, which is a potent and specific PFKFB3 inhibitor [13] that was used as a positive control clearly showed binding towards recombinant PFKFB3 (Figure 5).

Figure 5. 3PO does not bind to PFKFB3. Binding of 3PO to PFKFB3 was analyzed via calorimetry using a MicroCal ITC isothermal titration calorimeter. Discharged or absorbed heat during the eventual interaction between the PFKFB3 protein and 3PO was measured (Delta H). PFKFB3 inhibitor AZ PFKFB3 67 (3 µM) was used as a positive control. Indicated concentrations are the concentrations in the injection syringe of the Peaq-ITC.

3PO induces intracellular lactate accumulation and decreases the intracellular pH

Disruption of the intracellular pH (pHi) has been shown to play an important role in regulating angiogenesis [18] and glycolysis. [18, 19] Therefore, we studied the effect of 3PO treatment on the pHi in ECs. 3PO (20 µM) induced intracellular acidification, as shown by a significant decrease in pHi in HUVECs (Figure 6A). Given that lactate is an important regulator of pH [20], we measured intracellular lactate levels in HUVECs after treatment with 3PO and showed that it increased the lactate concentration intracellularly (Figure 6B). CHC, a well-known inhibitor of monocarboxylate transporters [21], was used as a reference compound.

148

Figure 6. 3PO interferes with intracellular pH. (A) 3PO induces intracellular lactate accumulation. Human umbilical vein endothelial cells (HUVECs) were treated with 3PO (20 µM) for 24 h. Lactate fluorescent substrate was added and fluorescence was measured, n=4-9. *P<0.05, ***P<0.001 vs. control (one-way ANOVA followed by Dunnett test). (B) 3PO decreases the intracellular pH. HUVECs were treated with 3PO (20 µM) for 5 h. Fluorescent pH indicator BCFL-AM was added and fluorescence was measured. CHC (2-Cyano-3-(4-hydroxyphenyl)-2-propenoic acid; 2 mM) was used as a positive control, n=6-20. ***P<0.001 vs. control (one-way ANOVA followed by Dunnett test).

Discussion

The rate of glycolysis in ECs is much higher than in any other healthy cell type. Accordingly, the majority of ATP produced in these cells is through the anaerobic glycolytic pathway. These findings highlight glycolysis inhibition as a promising anti-angiogenic strategy. Using computational techniques, 3PO was identified as a small-molecule inhibitor of PFKFB3. [6] Follow-up experiments indicate that 3PO reduces Fru-2,6-P_2 levels and glycolytic flux [6]. Since then, administration of 3PO has been considered as an attractive therapeutic strategy in cancer research, acute lung injury, lung fibrosis, and atherosclerosis. [22-25] The ability of 3PO to inhibit glycolysis was confirmed in the present study. Indeed, by using Seahorse technology, we could demonstrate that 3PO inhibits glycolysis in a concentration-dependent manner in HUVECs, resulting in an up to 50% reduction in glycolytic rate. Moreover, 3PO inhibits capillary tube formation, migration of ECs, and formation of aortic sprouts, which are all processes that heavily depend on glycolysis. However, an enzyme binding assay via isothermal titration calorimetry did not reveal binding of 3PO to PFKFB3, not even when titrating with up to 750 µM final concentration, which is more than 35 times higher than the 20 µM 3PO used in the *in cellulo* experiments. This raises considerable doubts as to whether 3PO does work via PFKFB3 inhibition. Importantly, 3PO does not inhibit the enzymatic activity of other enzymes involved in the glycolytic pathway, such as hexokinase, glucose 6-phosphate dehydrogenase, transketolase, glyceraldehyde 3-phosphate dehydrogenase, pyruvate kinase, and lactate dehydrogenase. The question remains which mechanism is responsible for the inhibition of glycolysis by 3PO. The present study shows that the inhibitory effect of 3PO on glycolysis relies on the ability of this compound to cause an imbalance in intracellular pH by accumulating lactic acid inside the cell. It is known that some glycolytic enzymes including lactate dehydrogenase and phosphofructokinase-1 (PFK-1) are very pH-sensitive. A change of less than one pH unit, even a few tenths, may reduce the activity of PFK-1 by more than 10-fold. [18, 19, 26-28] Moreover, PFKFB3, also known as phosphofructokinase-2 (PFK-2), has been shown to be allosterically regulated by hydrogen ion concentrations. [29] On the other hand, lactate is an important regulator of pH [20], hence the intracellular increase of this metabolite leads to intracellular milieu acidification, thus indirectly affecting the rate of glycolysis.

Manipulating intracellular acidification has been considered to have therapeutic utility in tumors. One of the strategies include the inhibition of monocarboxylate transporters (MCTs). Among different acid extruders present in the cell membrane, monocarboxylate transporters 1 and 4 are responsible for bumping out lactate and hydrogen ions. More specifically, a multitude of studies have documented that MCT1 or MCT4 inhibition conferred antiangiogenic effects and block tumor growth. [30-32] In this light, we do not rule out the possibility that 3PO acts as an inhibitor of one or more MCT transporters.

Altogether, our study indicates that the inhibitory effect of 3PO on PFKFB3 enzymatic activity, glycolysis, and angiogenesis is not mediated through direct binding to the PFKFB3 protein, as already suggested previously. [6] This is the first study to report these findings, as no previous studies have investigated the thermodynamic profile and biomolecular interactions of 3PO and PFKFB3. Intracellular acidification and lactate accumulation are followed by a chain reaction starting with MCT1/4 inhibition, pHi decrease, influence of pH dependent rate-limiting enzymes, and glycolysis suppression. This backward chain reaction supports our hypothesis of 3PO targeting MCT 1 and 4. The identification of this target may have an important impact on angiogenesis research and on the development of specific anti-angiogenic treatments, which has implications for a variety of pathologies.

Acknowledgements

References

1.   Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. *Experimental and molecular pathology*. 2009;86:174-179

2.   Sakakibara R, Kato M, Okamura N, Nakagawa T, Komada Y, Tominaga N, Shimojo M, Fukasawa M. Characterization of a human placental fructose-6-phosphate, 2-kinase/fructose-2,6-bisphosphatase. *Journal of biochemistry*. 1997;122:122-128

3.   Minchenko O, Opentanova I, Caro J. Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (pfkfb-1-4) expression in vivo. *FEBS letters*. 2003;554:264-270

4.   Obach M, Navarro-Sabate A, Caro J, Kong X, Duran J, Gomez M, Perales JC, Ventura F, Rosa JL, Bartrons R. 6-phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxia-inducible factor-1 binding sites necessary for transactivation in response to hypoxia. *The Journal of biological chemistry*. 2004;279:53562-53570

5.   De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, Quaegebeur A, Ghesquiere B, Cauwenberghs S, Eelen G, Phng LK, Betz I, Tembuyser B, Brepoels K, Welti J, Geudens I, Segura I, Cruys B, Bifari F, Decimo I, Blanco R, Wyns S, Vangindertael J, Rocha S, Collins RT, Munck S, Daelemans D, Imamura H, Devlieger R, Rider M, Van Veldhoven PP, Schuit F, Bartrons R, Hofkens J, Fraisl P, Telang S, Deberardinis RJ, Schoonjans L, Vinckier S, Chesney J, Gerhardt H, Dewerchin M, Carmeliet P. Role of pfkfb3-driven glycolysis in vessel sprouting. *Cell*. 2013;154:651-663

6.   Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, Rasku MA, Arumugam S, Dean WL, Eaton J, Lane A, Trent JO, Chesney J. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. *Molecular cancer therapeutics*. 2008;7:110-120

7. Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquiere B, Cauwenberghs S, Kuchnio A, Wong BW, Quaegebeur A, Goveia J, Bifari F, Wang X, Blanco R, Tembuyser B, Cornelissen I, Bouche A, Vinckier S, Diaz-Moralli S, Gerhardt H, Telang S, Cascante M, Chesney J, Dewerchin M, Carmeliet P. Partial and transient reduction of glycolysis by pfkfb3 blockade reduces pathological angiogenesis. *Cell metabolism*. 2014;19:37-48

8. Rao TN, Hansen N, Hilfiker J, Rai S, Majewska JM, Lekovic D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan TW, Lane AN, Handschin C, Dirnhofer S, Kroger N, Hess C, Radimerski T, Koschmieder S, Cokic VP, Skoda RC. Jak2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. *Blood*. 2019;134:1832-1846

9. Cao Y, Zhang X, Wang L, Yang Q, Ma Q, Xu J, Wang J, Kovacs L, Ayon RJ, Liu Z, Zhang M, Zhou Y, Zeng X, Xu Y, Wang Y, Fulton DJ, Weintraub NL, Lucas R, Dong Z, Yuan JX, Sullivan JC, Meadows L, Barman SA, Wu C, Quan J, Hong M, Su Y, Huo Y. Pfkfb3-mediated endothelial glycolysis promotes pulmonary hypertension. *Proceedings of the National Academy of Sciences of the United States of America*. 2019;116:13394-13403

10. Houddane A, Bultot L, Novellasdemunt L, Johanns M, Gueuning MA, Vertommen D, Coulie PG, Bartrons R, Hue L, Rider MH. Role of akt/pkb and pfkfb isoenzymes in the control of glycolysis, cell proliferation and protein synthesis in mitogen-stimulated thymocytes. *Cellular signalling*. 2017;34:23-37

11. Pisarsky L, Bill R, Fagiani E, Dimeloe S, Goosen RW, Hagmann J, Hess C, Christofori G. Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy. *Cell reports*. 2016;15:1161-1174

12. Finucane OM, Sugrue J, Rubio-Araiz A, Guillot-Sestier MV, Lynch MA. The nlrp3 inflammasome modulates glycolysis by increasing pfkfb3 in an il-1beta-dependent manner in macrophages. *Scientific reports*. 2019;9:4034

13. Boyd S, Brookfield JL, Critchlow SE, Cumming IA, Curtis NJ, Debreczeni J, Degorce SL, Donald C, Evans NJ, Groombridge S, Hopcroft P, Jones NP, Kettle JG, Lamont S, Lewis HJ, MacFaull P, McLoughlin SB, Rigoreau LJ, Smith JM, St-Gallay S, Stock JK, Turnbull AP, Wheatley ER, Winter J, Wingfield J. Structure-based design of potent and selective inhibitors of the metabolic kinase pfkfb3. *Journal of medicinal chemistry*. 2015;58:3611-3625

14. Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. *Nature protocols*. 2008;3:1125-1131

15. Zhang J, Nuebel E, Wisidagama DR, Setoguchi K, Hong JS, Van Horn CM, Imam SS, Vergnes L, Malone CS, Koehler CM, Teitell MA. Measuring energy metabolism in cultured cells, including human pluripotent stem cells and differentiated cells. *Nature protocols*. 2012;7:1068-1085

16. Divakaruni AS, Paradyse A, Ferrick DA, Murphy AN, Jastroch M. Analysis and interpretation of microplate-based oxygen consumption and ph data. *Methods in enzymology*. 2014;547:309-354

17. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D'Amico G, Jones DT, Vojnovic B, Hodivala-Dilke K. Use of the mouse aortic ring assay to study angiogenesis. *Nat Protoc*. 2011;7:89-104

18. White KA, Grillo-Hill BK, Barber DL. Cancer cell behaviors mediated by dysregulated ph dynamics at a glance. *Journal of cell science*. 2017;130:663-669

19. Quach CH, Jung KH, Lee JH, Park JW, Moon SH, Cho YS, Choe YS, Lee KH. Mild alkalization acutely triggers the warburg effect by enhancing hexokinase activity via voltage-dependent anion channel binding. *PloS one*. 2016;11:e0159529

20. Huber V, Camisaschi C, Berzi A, Ferro S, Lugini L, Triulzi T, Tuccitto A, Tagliabue E, Castelli C, Rivoltini L. Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation. *Seminars in cancer biology*. 2017;43:74-89

21.   Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. *The Journal of clinical investigation*. 2008;118:3930-3942

22.   Conradi LC, Brajic A, Cantelmo AR, Bouche A, Kalucka J, Pircher A, Bruning U, Teuwen LA, Vinckier S, Ghesquiere B, Dewerchin M, Carmeliet P. Tumor vessel disintegration by maximum tolerable pfkfb3 blockade. *Angiogenesis*. 2017;20:599-613

23.   Gong Y, Lan H, Yu Z, Wang M, Wang S, Chen Y, Rao H, Li J, Sheng Z, Shao J. Blockage of glycolysis by targeting pfkfb3 alleviates sepsis-related acute lung injury via suppressing inflammation and apoptosis of alveolar epithelial cells. *Biochemical and biophysical research communications*. 2017;491:522-529

24.   Xie N, Tan Z, Banerjee S, Cui H, Ge J, Liu RM, Bernard K, Thannickal VJ, Liu G. Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis. *American journal of respiratory and critical care medicine*. 2015;192:1462-1474

25.   Perrotta P, Van der Veken B, Van Der Veken P, Pintelon I, Roosens L, Adriaenssens E, Timmerman V, Guns PJ, De Meyer GRY, Martinet W. Partial inhibition of glycolysis reduces atherogenesis independent of intraplaque neovascularization in mice. *Arteriosclerosis, thrombosis, and vascular biology*. 2020:ATVBAHA119313692

26.   Andres V, Carreras J, Cusso R. Regulation of muscle phosphofructokinase by physiological concentrations of bisphosphorylated hexoses: Effect of alkalinization. *Biochemical and biophysical research communications*. 1990;172:328-334

27.   Kamp G, Schmidt H, Stypa H, Feiden S, Mahling C, Wegener G. Regulatory properties of 6-phosphofructokinase and control of glycolysis in boar spermatozoa. *Reproduction*. 2007;133:29-40

28. Trivedi B, Danforth WH. Effect of ph on the kinetics of frog muscle phosphofructokinase. *The Journal of biological chemistry*. 1966;241:4110-4112

29. Putney LK, Barber DL. Expression profile of genes regulated by activity of the na-h exchanger nhe1. *BMC genomics*. 2004;5:46

30. Hong CS, Graham NA, Gu W, Espindola Camacho C, Mah V, Maresh EL, Alavi M, Bagryanova L, Krotee PAL, Gardner BK, Behbahan IS, Horvath S, Chia D, Mellinghoff IK, Hurvitz SA, Dubinett SM, Critchlow SE, Kurdistani SK, Goodglick L, Braas D, Graeber TG, Christofk HR. Mct1 modulates cancer cell pyruvate export and growth of tumors that co-express mct1 and mct4. *Cell reports*. 2016;14:1590-1601

31. Sonveaux P, Copetti T, De Saedeleer CJ, Vegran F, Verrax J, Kennedy KM, Moon EJ, Dhup S, Danhier P, Frerart F, Gallez B, Ribeiro A, Michiels C, Dewhirst MW, Feron O. Targeting the lactate transporter mct1 in endothelial cells inhibits lactate-induced hif-1 activation and tumor angiogenesis. *PloS one*. 2012;7:e33418

32. Voss DM, Spina R, Carter DL, Lim KS, Jeffery CJ, Bar EE. Disruption of the monocarboxylate transporter-4-basigin interaction inhibits the hypoxic response, proliferation, and tumor progression. *Scientific reports*. 2017;7:4292